51.41
2.74%
1.37
Dopo l'orario di chiusura:
51.60
0.19
+0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$50.04
Aprire:
$49.81
Volume 24 ore:
483.62K
Relative Volume:
0.51
Capitalizzazione di mercato:
$5.05B
Reddito:
-
Utile/perdita netta:
$-746.61M
Rapporto P/E:
-6.8822
EPS:
-7.47
Flusso di cassa netto:
$-485.24M
1 W Prestazione:
+0.90%
1M Prestazione:
+7.94%
6M Prestazione:
+26.35%
1 anno Prestazione:
+66.81%
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-09-16 | Iniziato | Jefferies | Buy |
2024-09-04 | Iniziato | Bernstein | Outperform |
2024-07-24 | Iniziato | Morgan Stanley | Overweight |
2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
2024-02-06 | Iniziato | UBS | Buy |
2023-12-22 | Iniziato | H.C. Wainwright | Buy |
2023-12-08 | Iniziato | Robert W. Baird | Outperform |
2023-01-24 | Iniziato | SVB Securities | Outperform |
2023-01-04 | Iniziato | JP Morgan | Overweight |
2022-12-02 | Iniziato | BTIG Research | Buy |
2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2022-10-12 | Iniziato | Piper Sandler | Overweight |
2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
2021-08-10 | Downgrade | UBS | Buy → Neutral |
2021-08-03 | Reiterato | Canaccord Genuity | Buy |
2021-03-11 | Iniziato | UBS | Buy |
2020-12-15 | Iniziato | H.C. Wainwright | Buy |
2020-04-17 | Iniziato | Cowen | Outperform |
2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
2020-02-06 | Iniziato | Mizuho | Buy |
2019-11-22 | Iniziato | Wedbush | Outperform |
2019-06-25 | Reiterato | Canaccord Genuity | Buy |
2019-05-06 | Iniziato | Goldman | Buy |
2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2019-03-04 | Reiterato | Needham | Buy |
2018-07-03 | Reiterato | Needham | Buy |
2018-07-02 | Reiterato | Needham | Buy |
2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
2018-02-22 | Reiterato | Canaccord Genuity | Buy |
2017-12-15 | Iniziato | Canaccord Genuity | Buy |
2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Vanguard Group Inc's Strategic Acquisition in Biohaven Ltd - GuruFocus.com
(BHVN) Technical Data - Stock Traders Daily
Cadent Capital Advisors LLC Invests $1.77 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
(BHVN) Trading Advice - Stock Traders Daily
Scholar Rock stock could benefit from Biohaven's Ph3 results, Truist raises potential rally outlook - Investing.com India
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside By Investing.com - Investing.com South Africa
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com UK
Biohaven Ltd. (NYSE:BHVN) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by AQR Capital Management LLC - MarketBeat
(BHVN) Investment Analysis - Stock Traders Daily
17,064 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Squarepoint Ops LLC - MarketBeat
Biohaven retains Outperform stock rating on clinical results By Investing.com - Investing.com South Africa
Biohaven holds steady with $60 target on SMA trial optimism - Investing.com India
Biohaven holds steady with $60 target on SMA trial optimism By Investing.com - Investing.com Australia
Biohaven maintains Buy rating with $59 target amid SMA trial optimism By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Up 4.9%Here's What Happened - MarketBeat
Vladimir Coric Buys Handful Of Shares In Biohaven - Simply Wall St
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN
Cantor Fitzgerald Reiterates "Overweight" Rating for Biohaven (NYSE:BHVN) - MarketBeat
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN
Analysts’ Recent Ratings Changes for Biohaven (BHVN) - Defense World
Biohaven (NYSE:BHVN) Price Target Raised to $68.00 at JPMorgan Chase & Co. - MarketBeat
Biohaven (NYSE:BHVN) Shares Gap Up After Insider Buying Activity - MarketBeat
John W. Childs Purchases 21,052 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - Defense World
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Yahoo Finance
Biohaven director Childs buys shares worth nearly $1 million By Investing.com - Investing.com South Africa
Biohaven CEO Vlad Coric acquires $999,970 in company stock By Investing.com - Investing.com Australia
Biohaven director Childs buys shares worth nearly $1 million - Investing.com
Biohaven CEO Vlad Coric acquires $999,970 in company stock - Investing.com India
Marshall Wace LLP Sells 677,724 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Lelezard.com
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Biohaven sets public offering price at $47.50 per share By Investing.com - Investing.com Australia
Biohaven shares could see growth as MDD and bipolar studies advance, per TD Cowen - Investing.com India
Biohaven (NYSE:BHVN) Sees Strong Trading Volume - MarketBeat
Biohaven sets public offering price at $47.50 per share - Investing.com
Biohaven down after $250 mln stock offering prices - XM
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - Nasdaq
Biohaven launches $250 million public stock offering By Investing.com - Investing.com Australia
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust By Investing.com - Investing.com South Africa
Biohaven launches $250 million public stock offering - Investing.com India
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust - Investing.com India
Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire
Biohaven starts phase 2 trial for new migraine treatment - Investing.com India
Biohaven starts phase 2 trial for new migraine treatment By Investing.com - Investing.com UK
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - PR Newswire
Driehaus Capital Management LLC Lowers Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Indo-Asian News Service - IANS India Pvt Ltd
Biohaven, Tesla And Other Big Stocks Moving Higher On Monday - MSN
97,902 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by Cubist Systematic Strategies LLC - Defense World
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):